Neurotech Pharmaceuticals, Inc. is a privately held biotech company located in Cumberland, Rhode Island. Neurotech has spent years developing the science, technology, team and manufacturing behind NT-501. As a result of a unique partnership and clear direction, we are focused on bringing a long-term treatment to Macular Telangiectasia (MacTel) patients.  Our team is focused on bringing to market this treatment designed to slow the progression of MacTel and the vision impairments it causes in patients who don't have another treatment option. Our goal is to help these patients sustain their quality of life.

Biotechnology

Neurotech Pharmaceuticals, Inc.

Richard Small

Paul Brannelly

Lovisa Selander

Brett Aguiar

Matthew Fera

Andrew Vitorino Ormonde

Jacob Patterson Esq.

Arne Nystuen

Patricia Davis (Patty)

Terry McCurren

Derek Barnett

Sean K.

Scott Bertolami

The Quality Control team at Neurotech Pharmaceuticals, Inc. is responsible for ensuring that all products, including the NT-501 treatment for Macular Telangiectasia (MacTel), meet stringent quality standards and regulatory requirements. They perform rigorous testing and analysis throughout the manufacturing process, monitor compliance with Good Manufacturing Practices (GMP), and manage supplier quality to ensure the efficacy and safety of the treatments brought to market.

Quality Control

Quality and Compliance Team

Clinical and Market Access Team

Quality Control

About

Team members

Other teams at Neurotech Pharmaceuticals, Inc.

Quality and Compliance Team

Clinical and Market Access Team